

Condensed Consolidated Statements of Earnings (Unaudited)

Dollars in millions, except per share data

	Three months ended		Nine months ended	
	03/31/2024	03/31/2023	3/31/2024	3/31/2023
Net sales	\$ 1,814	\$ 1,915	\$ 5,190	\$ 5,370
Cost of products sold	1,048	1,115	3,026	3,324
Gross profit	766	800	2,164	2,046
Selling and administrative expenses	301	311	899	854
Advertising costs	215	206	566	523
Research and development costs	32	35	93	100
Loss on divestiture	240	—	240	—
Pension settlement charge	—	—	171	—
Goodwill, trademark and other intangible asset impairments	—	445	—	445
Interest expense	22	24	69	69
Other (income) expense, net	(2)	24	3	54
Earnings (losses) before income taxes	(42)	(245)	123	1
Income tax expense (benefit)	8	(36)	52	21
Net earnings (losses)	(50)	(209)	71	(20)
Less: Net earnings attributable to noncontrolling interests	1	2	7	7
Net earnings (losses) attributable to Clorox	\$ (51)	\$ (211)	\$ 64	\$ (27)
Net earnings (losses) per share attributable to Clorox				
Basic net earnings (losses) per share	\$ (0.41)	\$ (1.71)	\$ 0.52	\$ (0.22)
Diluted net earnings (losses) per share	\$ (0.41)	\$ (1.71)	\$ 0.52	\$ (0.22)
Weighted average shares outstanding (in thousands)				
Basic	124,249	123,649	124,133	123,512
Diluted	124,249	123,649	124,721	123,512

Reportable Segment Information
(Unaudited)

Dollars in millions

	Net sales			Net sales		
	Three months ended			Nine months ended		
	3/31/2024	3/31/2023	% Change ⁽¹⁾	3/31/2024	3/31/2023	% Change ⁽¹⁾
Health and Wellness	\$ 609	\$ 647	(6)%	\$ 1,833	\$ 1,881	(3)%
Household	526	550	(4)	1,353	1,435	(6)
Lifestyle	315	353	(11)	947	1,005	(6)
International	310	305	2	891	876	2
Corporate and Other ⁽²⁾	54	60	(10)	166	173	(4)
Total	\$ 1,814	\$ 1,915	(5)%	5,190	\$ 5,370	(3)%
	Segment adjusted EBIT			Segment adjusted EBIT		
	Three months ended			Nine months ended		
	3/31/2024	3/31/2023	% Change ⁽¹⁾	3/31/2024	3/31/2023	% Change ⁽¹⁾
Health and Wellness	\$ 154	\$ 161	(4)%	\$ 517	\$ 418	24 %
Household	74	99	(25)	162	165	(2)
Lifestyle	64	83	(23)	192	217	(12)
International	38	27	41	104	74	41
Corporate and Other ⁽²⁾	(70)	(101)	31	(238)	(251)	5
Total	\$ 260	\$ 269	(3)%	737	\$ 623	18 %
Interest income	4	4		21	9	
Interest expense	(22)	(24)		(69)	(69)	
Loss on divestiture ⁽³⁾	(240)	—		(240)	—	
Pension settlement ⁽⁴⁾	—	—		(171)	—	
Cyberattack costs ⁽⁵⁾	(8)	—		(57)	—	
VMS impairment ⁽⁶⁾	—	(445)		—	(445)	
Streamlined operating model ⁽⁷⁾	(10)	(21)		(13)	(44)	
Digital capabilities and productivity enhancements investment ⁽⁸⁾	(26)	(28)		(85)	(73)	
Earnings (losses) before income taxes	\$ (42)	\$ (245)	(83)%	\$ 123	\$ 1	12,200 %

⁽¹⁾ Percentages based on rounded numbers.

⁽²⁾ Corporate and Other includes the Vitamin, Minerals and Supplements business.

⁽³⁾ Represents the loss on divestiture of Argentina operations of \$240 (\$231 after tax) for the three and nine months ended Mar. 31, 2024.

⁽⁴⁾ Represents the pension settlement charge of \$171 (\$130 after tax) for the nine months ended Mar. 31, 2024.

⁽⁵⁾ Represents costs related to the cyberattack of \$8 (\$6 after tax) and \$57 (\$43 after tax) for the three and nine months ended Mar. 31, 2024, respectively.

⁽⁶⁾ Represents a \$445 (\$362 after tax) noncash impairment charge related to the VMS business for the three and nine months ended March 31, 2023.

⁽⁷⁾ Represents restructuring and related costs, net for implementation of the streamlined operating model of \$10 (\$7 after tax) and \$13 (\$10 after tax) for the three and nine months ended Mar. 31, 2024, and \$21 (\$17 after tax) and \$44 (\$34 after tax) for the three and nine months ended Mar. 31, 2023, respectively.

⁽⁸⁾ Represents expenses related to the company's digital capabilities and productivity enhancements investment of \$26 (\$20 after tax) and \$85 (\$64 after tax) for the three and nine months ended Mar. 31, 2024, and \$28 (\$20 after tax) and \$73 (\$55 after tax) for the three and nine months ended Mar. 31, 2023, respectively.

Condensed Consolidated Balance Sheets

Dollars in millions

	3/31/2024	6/30/2023	3/31/2023
	(Unaudited)		(Unaudited)
ASSETS			
Current assets			
Cash and cash equivalents	\$ 219	\$ 367	\$ 242
Receivables, net	673	688	678
Inventories, net	674	696	735
Prepaid expenses and other current assets	95	77	90
Total current assets	1,661	1,828	1,745
Property, plant and equipment, net	1,292	1,345	1,315
Operating lease right-of-use assets	379	346	359
Goodwill	1,229	1,252	1,250
Trademarks, net	539	543	546
Other intangible assets, net	149	169	176
Other assets	556	462	427
Total assets	<u>\$ 5,805</u>	<u>\$ 5,945</u>	<u>\$ 5,818</u>
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities			
Notes and loans payable	\$ 111	\$ 50	\$ 138
Current operating lease liabilities	82	87	88
Accounts payable and accrued liabilities	1,653	1,659	1,722
Income Taxes Payable	—	121	48
Total current liabilities	1,846	1,917	1,996
Long-term debt	2,480	2,477	2,476
Long-term operating lease liabilities	347	310	323
Other liabilities	853	825	824
Deferred income taxes	24	28	27
Total liabilities	5,550	5,557	5,646
Commitments and contingencies			
Stockholders' equity			
Preferred stock	—	—	—
Common stock	131	131	131
Additional paid-in capital	1,270	1,245	1,232
Retained earnings	34	583	415
Treasury stock	(1,189)	(1,246)	(1,277)
Accumulated other comprehensive net (loss) income	(155)	(493)	(498)
Total Clorox stockholders' equity	91	220	3
Noncontrolling interests	164	168	169
Total stockholders' equity	255	388	172
Total liabilities and stockholders' equity	<u>\$ 5,805</u>	<u>\$ 5,945</u>	<u>\$ 5,818</u>